Multi-omics insights into gut microbial dysbiosis and metabolic alterations in immune checkpoint inhibitor-induced thrombocytopenia

Key Points

• The research investigates how gut microbial changes and metabolic alterations relate to thrombocytopenia induced by immune checkpoint inhibitors.
• Analyzed gut microbial profiles through multi-omics techniques.
• Examined arginine levels in relation to thrombocytopenia.
• Identified metabolic disruptions associated with immune checkpoint inhibitor treatments.
• Found significant loss of arginine linked to thromobcytopenia risk.
• Demonstrated gut microbial dysbiosis in patients receiving immune checkpoint inhibitors.
• Suggested that targeting arginine depletion could help mitigate thrombocytopenia.